Cytophage Technologies Ltd (CYTO.V)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of CA$10,000 in Cytophage Technologies Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Cytophage Technologies Ltd (CYTO.V) has returned -60.00% so far this year and -57.14% over the past 12 months.

Based on dividend-adjusted daily data since Feb 9, 2024, CYTO.V's average daily return is -0.20%, while the average monthly return is -5.78%.

Historically, 31% of months were positive and 69% were negative. The best month was Apr 2025 with a return of +64.3%, while the worst month was Mar 2026 at -42.9%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.

On a daily basis, CYTO.V closed higher 33% of trading days. The best single day was Jan 13, 2026 with a return of +42.3%, while the worst single day was Mar 17, 2026 at -31.6%.

Cytophage Technologies Ltd has an annualized alpha of -40.01%, beta of 0.04, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 12, 2024.

• This stock participated in 341.20% of S&P 500 Index downside but only -74.25% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.04 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CYTO.V ranks 20 for risk / return — below 20% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Cytophage Technologies Ltd (CYTO.V) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cytophage Technologies Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cytophage Technologies Ltd was 92.06%, occurring on Mar 19, 2026. The portfolio has not yet recovered.

The current Cytophage Technologies Ltd drawdown is 90.48%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cytophage Technologies Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cytophage Technologies Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.